Phase 2 N=305 BARDA Securing Anthrax Immunity For the Elderly
Anthrax
Primary: Solicited Local Reactogenicity Symptoms — 46; 43; 40; 45 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer
Breast Cancer
Primary: Compare Per Subject Average Area Under the ROC (Receiver Operating Characteristic) Curve (AUC) — 0.819; 0.796 Probability — p=<0.01
N/A N=104 rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities
Sexually Transmitted Infection
Primary: Change in Frequency of Recent Dual Method Use — 3.17; 3.45 score on a scale — p=.177
Phase 3 N=158 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Tourette Syndrome
Primary: Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants — -7.8; -7.0 units on a scale…
Phase 1 N=30 Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B
Malaria
Primary: Number of Participants With Solicited Adverse Events With Each Vaccination by Grade — 0; 0; 0; 0 Participants
Phase 3 N=1,121 Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Migraine Disorders
Primary: Change From Baseline in Monthly Migraine Days — -8.2; -7.7; -5.6 Migraine Days — p=<0.0001
Phase 4 N=42 Evaluation of Efficacy of Full-mouth Disinfection in Generalized Aggressive Periodontitis Patients
Aggressive Periodontitis
Primary: Probing Depth — 4.55; 4.80; 4.90; 2.71 mm — p=<0.01
Phase 4 N=164 Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery
Catheter-Associated Urinary Tract Infection
Primary: UTI — 15; 14 Participants — p=0.84
Phase 2 N=1,715 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y…
N/A N=28 T-DOC® 5 Fr Pediatric Clinical Investigation
Incontinence, Urge
Primary: The Number of Patients in Which the T-DOC® 5 Fr Catheters Are Safe in Measuring Urodynamic Pressures in Pediatric Subjects (12 Years of Age and Younger). — 28 Participants
Phase 2 N=56 Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Sarcoma, Soft Tissue · Soft Tissue Sarcoma
Primary: Clinical Benefit Rate — 22 Participants
N/A N=80 Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study
Diabetes Mellitus, Type 1
Primary: Feasibility of Study Design - Recruitment Rate — 84 Participants
N/A N=20 T-DOC® NXT Clinical Investigation
Incontinence, Urge
Primary: The Number of Patients in Which the T-DOC® NXT Catheters Are Safe in Measuring Urodynamic Pressure in Adults. — 20 Participants
Phase 2 N=580 A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
Meningitis · Meningococcal Infection
Primary: Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer Greater or Than Equal to (≥) 1:8 and ≥1:4: Groups 1, 2, 3, 4, 6…
Phase 2 N=22 RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Prostate Cancer
Primary: Proportions of Participants With Treatment-related Adverse Events — 22 Participants